Semaglutide is a glucagon-like peptide 1 (GLP-1) analogue, which improves MASLD indirectly by ameliorating obesity, as there is no hepatic expression of GLP-1 receptors.16 The gene discussed is GLP1R; the disease is obesity disorder.